Skip to content

Multicenter study of vincristine replace corticosteroids as first-line treatment for Kaposiform Hemangioendothelioma

Multicenter study of vincristine replace corticosteroids as first-line treatment for Kaposiform Hemangioendothelioma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008223
Enrollment
Unknown
Registered
2016-04-05
Start date
2016-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kaposiform Hemangioendothelioma

Interventions

Corticosteroid group:Use corticosteroid for therapy
VCR group:Use VCR for therapy

Sponsors

Children‘s Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 12 Years

Inclusion criteria

Inclusion criteria: Kaposiform Hemangioendothelioma diagnosed by clinical and pathology; males and females, aged 0-12 years; signed the informed consent before treatment; donn't receive any other treatment

Exclusion criteria

Exclusion criteria: Suffering from hematological diseases and other solid tumors; Suffering from hypertension, diabetes, adrenal cortex function insufficiency, nervous system disorders, liver and kidney function insufficiency and heart and lung function insufficiency; Suffering from tuberculosis, CMV and EB virus infection before treatment; receiving any other treatment

Design outcomes

Primary

MeasureTime frame
Platelet;Coagulation function;MRI;Ultrasound;CT scan;Tumor size;

Secondary

MeasureTime frame
Tumor texture;Purpura of tumor;colour and lustre of tumor;

Countries

China

Contacts

Public ContactLi Kai

Children's Hospital of Fudan University

likai2727@163.com+86 18017591001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026